《大行》高盛将润啤(00291.HK)及印度NTPC纳入亚太地区确信名单剔除盐野义制药及康哲药业(00867.HK)

阿斯达克财经04-09

高盛发表研究报告指，将华润啤酒(00291.HK) 及印度NTPC纳入亚太地区确信名单，并同时剔除盐野义制药及康哲药业(00867.HK) 。该行预期，润啤将在经营高端啤酒业务的同行中获得最大市场份额提升，并在2024至26年达到高端销售增长约11%，带动集团于期内销售额及净利润复合年增长率分别为5%和16%。至于NTPC，该行预计集团将受惠于中期内高峰电力短缺加剧引致的重新评级及可再生能源转型。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2426490739?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112152951051_s.jpg","is_english":false,"pubTime":"2024-04-09 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426490739","market":"other","top_or_hot":-1,"title":"《大行》高盛将润啤(00291.HK)及印度NTPC纳入亚太地区确信名单  剔除盐野义制药及康哲药业(00867.HK)","media":"阿斯达克财经","content":"<div>\n<p>高盛发表研究报告指，将华润啤酒(00291.HK) 及印度NTPC纳入亚太地区确信名单，并同时剔除盐野义制药及康哲药业(00867.HK) 。该行预期，润啤将在经营高端啤酒业务的同行中获得最大市场份额提升，并在2024至26年达到高端销售增长约11%，带动集团于期内销售额及净利润复合年增长率分别为5%和16%。至于NTPC，该行预计集团将受惠于中期内高峰电力短缺加剧引致的重新评级及可再生能源转型。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340889/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》高盛将润啤(00291.HK)及印度NTPC纳入亚太地区确信名单  剔除盐野义制药及康哲药业(00867.HK)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》高盛将润啤(00291.HK)及印度NTPC纳入亚太地区确信名单  剔除盐野义制药及康哲药业(00867.HK)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-09 10:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340889/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表研究报告指，将华润啤酒(00291.HK) 及印度NTPC纳入亚太地区确信名单，并同时剔除盐野义制药及康哲药业(00867.HK) 。该行预期，润啤将在经营高端啤酒业务的同行中获得最大市场份额提升，并在2024至26年达到高端销售增长约11%，带动集团于期内销售额及净利润复合年增长率分别为5%和16%。至于NTPC，该行预计集团将受惠于中期内高峰电力短缺加剧引致的重新评级及可再生能源转型。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340889/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340889/latest-news/AAFN","article_id":"2426490739","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112152951051_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426490739","pubTimestamp":1712628180,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"高盛发表研究报告指，将华润啤酒(00291.HK) 及印度NTPC纳入亚太地区确信名单，并同时剔除盐野义制药及康哲药业(00867.HK) 。该行预期，润啤将在经营高端啤酒业务的同行中获得最大市场份额提升，并在2024至26年达到高端销售增长约11%，带动集团于期内销售额及净利润复合年增长率分别为5%和16%。至于NTPC，该行预计集团将受惠于中期内高峰电力短缺加剧引致的重新评级及可再生能源转型。(sl/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-08 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"80291":"华润啤酒-R五百","BK4127":"投资银行业与经纪业","01477":"欧康维视生物-B","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK1510":"啤酒","BK1180":"啤酒酿造商","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","CRHKY":"华润啤酒ADR","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK1589":"北水核心资产","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","00867":"康哲药业","BK4533":"AQR资本管理(全球第二大对冲基金)","BK1583":"高瓴概念","BK1604":"节假日概念","IE0008368742.USD":"首域中国增长基金I Acc","LU1720050803.USD":"安联全方位中国股票基金","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","BK1570":"华润系","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK4552":"Archegos爆仓风波概念","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0106831901.USD":"贝莱德世界金融基金A2","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999006514.SGD":"United Asia Consumer Fund SGD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","BK1593":"医美概念股","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1578":"个体经济","SG9999015978.USD":"利安颠覆性创新基金A","BK4504":"桥水持仓","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","00291":"华润啤酒-五百","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC"},"translate_title":"\"Big Bank\" Goldman Sachs included Runpi (00291. HK) and Indian NTPC in the Asia-Pacific region convinced list, excluding Shionogi Pharmaceutical and Kang Zhe Pharmaceutical (00867. HK)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"80291":0.6,"00867":1,"01477":1,"00291":1,"CRHKY":0.6},"content_text":"高盛发表研究报告指，将华润啤酒(00291.HK) 及印度NTPC纳入亚太地区确信名单，并同时剔除盐野义制药及康哲药业(00867.HK) 。该行预期，润啤将在经营高端啤酒业务的同行中获得最大市场份额提升，并在2024至26年达到高端销售增长约11%，带动集团于期内销售额及净利润复合年增长率分别为5%和16%。至于NTPC，该行预计集团将受惠于中期内高峰电力短缺加剧引致的重新评级及可再生能源转型。(sl/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-08 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426490739"}

《大行》高盛将润啤(00291.HK)及印度NTPC纳入亚太地区确信名单 剔除盐野义制药及康哲药业(00867.HK)

精彩评论

《大行》高盛将润啤(00291.HK)及印度NTPC纳入亚太地区确信名单剔除盐野义制药及康哲药业(00867.HK)